ArticleGut2024

Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes.

Axel Wester et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.